Pseudomonas aeruginosa keratitis: passive immunotherapy with antibodies raised against divalent flagellin

Document Type: Original Article

Authors

1 Department of Microbiology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran

2 Department of Microbiology, Biology Research Center, Zanjan Branch, Islamic Azad University, Zanjan, Iran

3 Medical Biotechnology Research Center, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran

Abstract

Objective(s): Pseudomonas aeruginosa infections such as keratitis are considered among the major health problems worldwide due to the complexity of pathogenesis and antibiotic resistance crisis, thus, finding new effective approaches for prevention and treatment of the infections seem to be still vital. In this report, we aimed to investigate the therapeutic effects of topical administration of the antibodies against type a and b-flagellin (FLA and FLB) in Pseudomonas keratitis model of infection in mice.
Materials and Methods: Scratched corneas of mice were treated with approximately 107 CFUs/eye of PAK and/or PAO1 strains of P. aeruginosa. Specific IgG to FLA, FLB or divalent flagellin were topically applied to the infected corneas for 20 min, 24, and 36 hr post-infection. The bacterial burden and myeloperoxidase activity (as a marker for polymorphonuclears (PMNs) infiltration) were determined in the corneas. The biological activity of the anti-FLA and FLB IgG was evaluated in vitro by opsonophagocytosis test.
Results: Compared to other treated corneas, divalent anti-flagellin IgG treatment showed a significant decrease in the bacterial CFUs and myeloperoxidase activity in the infected corneas (P<0.05). Results of opsonophagocytosis revealed that the specific antibodies raised against FLA and FLB had more potent opsonic killing activity on their homologous strains as compared with control group (P<0.05).
Conclusion: It appears that in P. aeruginosa keratitis, topical administration of the combined antibodies likely via decreasing the bacterial load, and PMNs infiltration as well as increasing opsonophagocytosis could lead to dramatic improvement of the infected corneas.

Keywords

Main Subjects


1. Rachwalik D, Pleyer U. [Bacterial Keratitis]. Klin Monbl Augenheilkd 2015; 232:738-744.
2. Taher EE, Mahmoud NF, Negm S, Abdallah I. Severe, sight threatening microbial keratitis: coinfection of acanthamoeba and Pseudomonas in contact lens associated keratitis. Adv Environ Biol 2016; 10:231-240.
3. Zhou C, Chen X, Wu L, Qu J. Distribution of drug-resistant bacteria and rational use of clinical antimicrobial agents. Exp Ther Med 2016; 11:2229-2232.
4. Lakhundi S, Siddiqui R, Khan NA. Pathogenesis of microbial keratitis. Microb Pathog 2017; 104:97-109.
5. Redfern RL, McDermott AM. Toll-like receptors in ocular surface disease. Exp Eye Res 2010; 90:679-687.
6. Chin AC, Parkos CA. Pathobiology of neutrophil transepithelial migration: implications in mediating epithelial injury. Annu Rev Pathol Mech Dis 2007; 2:111-143.
7. Rada B. Interactions between neutrophils and Pseudomonas aeruginosa in cystic fibrosis. Pathogens 2017; 6:1-24.
8. Sun Y, Karmakar M, Roy S, Ramadan RT, Williams SR, Howell S, et al. TLR4 and TLR5 on corneal macrophages regulate Pseudomonas aeruginosa keratitis by signaling through MyD88-dependent and -independent pathways. J Immunol 2010; 185:4272-4283.
9. Conrad JC, Gibiansky ML, Jin F, Gordon VD, Motto DA, Mathewson MA, et al. Flagella and pili-mediated near-surface single-cell motility mechanisms in Pseudomonas aeruginosa. Biophys J 2011; 100:1608-1616.
10. Vijay-Kumar M, Gewirtz AT. Flagellin: key target of mucosal innate immunity. Mucosal Immunol 2009; 2:197-205.
11. Krachler AM, Orth K. Targeting the bacteria–host interface: strategies in anti-adhesion therapy. Virulence 2013; 4:284-294.
12. Brimer CD, Montie TC. Cloning and comparison of fliC genes and identification of glycosylation in the flagellin of Pseudomonas aeruginosa a-type strains. J Bacteriol 1998; 180:3209-3217.
13. Campodonico VL, Llosa NJ, Grout M, Doring G, Maira-Litran T, Pier GB. Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines. Infect Immun 2010; 78:746-755.
14. Yu FS, Cornicelli MD, Kovach MA, Newstead MW, Zeng X, Kumar A, et al. Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J Immunol 2010; 185:1142-1149.
15. Sabharwal N, Chhibber S, Harjai K. New possibility for providing protection against urinary tract infection caused by Pseudomonas aeruginosa by non-adjuvanted flagellin ‘b’ induced immunity. Immunol Lett 2014; 162:229-238.
16. Gao N, Kumar A, Guo H, Wu X, Wheater M, Yu FS. Topical flagellin-mediated innate defense against Candida albicans keratitis. Invest Ophthalmol Vis Sci 2011; 52:3074-3082.
17. Kumar A, Hazlett LD, Yu FS. Flagellin suppresses the inflammatory response and enhances bacterial clearance in a murine model of Pseudomonas aeruginosa keratitis. Infect Immun 2008; 76:89-96.
18. Campodonico VL, Llosa NJ, Bentancor LV, Maira-Litran T, Pier GB. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice. Infect Immun 2011; 79:3455-3464.
19. Faezi S, Safarloo M, Behrouz B, Amirmozafari N, Nikokar I, Mahdavi M. Comparison between active and passive immunization with flagellin-based subunit vaccine from Pseudomonas aeruginosa in the burned-mouse model. Iran J Clin Infect Dis 2013; 7:10-16.
20. Holder IA, Naglich JG. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: immunization using divalent flagella preparations. J Trauma 1986; 26:118-122.
21. Sabharwal N, Chhibber S, Harjai K. Divalent flagellin immunotherapy provides homologous and heterologous protection in experimental urinary tract infections in mice. Int J Med Microbiol 2016; 306:29-37.
22. Doring G, Dorner F. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis. Behring Inst Mitt 1997; 98:338-344.
23. Faezi S, Bahrmand AR, Mahdavi M, Siadat SD, Nikokar I, Sardari S, et al. High yield overexpression, refolding, purification and characterization of Pseudomonas aeruginosa type B-flagellin: an improved method without sonication. Int J Mol Cell Med 2016; 5:37-48.
24. Faezi S, Bahrmand AR, Mahdavi M, Siadat SD, Sardari S, Nikokar I, et al. Preparation of Pseudomonas aeruginosa alginate-flagellin immunoconjugate. Biologicals 2017; 47:11-17.
25. Hazlett LD. Corneal response to Pseudomonas aeruginosa infection. Prog Retin Eye Res 2004; 23:1-30.
26. Leenaars M, Hendriksen CF. Critical steps in the production of polyclonal and monoclonal antibodies: evaluation and recommendations. Ilar J 2005; 46:269-279.
27. Zaidi T, Reidy T, D’Ortona S, Fichorova R, Pier G, Gadjeva M. CD74 deficiency ameliorates Pseudomonas aeruginosa-induced ocular infection. Sci Rep 2011; 1:1-7.
28. Kumar A, Hazlett LD, Fu-Shin XY. Flagellin suppresses the inflammatory response and enhances bacterial clearance in a murine model of Pseudomonas aeruginosa keratitis. Infect Immun 2008; 76:89-96.
29. Williams R, Paterson C, Eakins K, Bhattacherjee P. Quantification of ocular inflammation: evaluation of polymorphonuclear leucocyte infiltration by measuring myeloperoxidase activity. Curr Eye Res 1982; 2:465-470.
30. Fleiszig SM, Kwong MS, Evans DJ. Modification of Pseudomonas aeruginosa interactions with corneal epithelial cells by human tear fluid. Infect Immun 2003; 71:3866-3874.
31. Kumar A, Gao N, Standiford TJ, Gallo RL, Fu-Shin XY. Topical flagellin protects the injured corneas from Pseudomonas aeruginosa infection. Microbes Infect 2010; 12:978-989.
32. Augustin DK, Heimer SR, Tam C, Li WY, Le Due JM, Evans DJ, et al. Role of defensins in corneal epithelial barrier function against Pseudomonas aeruginosa traversal. Infect Immun 2011; 79:595-605.
33. Huang LC, Reins RY, Gallo RL, McDermott AM. Cathelicidin-deficient (Cnlp−/−) mice show increased susceptibility to Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2007; 48:4498-4508.
34. Atif SM, Lee SJ, Li LX, Uematsu S, Akira S, Gorjestani S, et al. Rapid CD4+ T‐cell responses to bacterial flagellin require dendritic cell expression of Syk and CARD9. Eur J Immunol 2015; 45:513-524.
35. Salazar-Gonzalez RM, McSorley SJ. Salmonella flagellin, a microbial target of the innate and adaptive immune system. Immunol Lett 2005; 101:117-122.
36. Hazlett LD, McClellan S, Goshgarian C, Huang X, Thakur A, Barrett R. The role of nitric oxide in resistance to Pseudomonas aeruginosa ocular infection. Ocul Immunol Inflamm 2005; 13:279-288.
37. Miller WL, Matewish MJ, McNally DJ, Ishiyama N, Anderson EM, Brewer D, et al. Flagellin glycosylation in Pseudomonas aeruginosa PAK requires the O-antigen biosynthesis enzyme WbpO. J Biol Chem 2008; 283:3507-3518.